1155 results about "Ovary" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention provides a method for preparing a chicken immortalized cell line. The method comprises the following steps: constructing a plasmid system of conditional over-expression TERT (Telomerase Reverse Transcriptase), carrying out ovarian injection and breeding to obtain a transgenic chicken of the conditional over-expression TERT, and carrying out separation and induction to obtain the chicken immortalized cell line. The obtained chicken immortalized cell line has the characteristics of primary cells and is susceptible to viruses; the method can be used for virus reproduction and detection, influenza virus vaccine production and the like, can obtain immortalized cell lines of all organs and all parts of the chicken in a short time, and has a good application prospect in the vaccine industry.

The invention provides a breeding method of golden and tiger hybrid spotted fish eggs. The breeding method comprises the following steps: S1, parent screening; s2, parent cultivation; s3, artificial insemination: (1) spawning induction: when the belly of the female parent fish expands, the ovary develops to the IV stage and the male parent fish presses the belly to cause white seminal fluid to flow out, performing oxygenation flowing water stimulation on the female parent fish, and performing irradiation with a TDP radiation lamp for spawning induction; (2) fertilization; s4, artificial incubation: (1) arranging an incubator, injecting seawater, and performing plasma treatment to obtain a treated incubator; and (2) adding the fertilized eggs into the treated incubator, carrying out magnetization treatment, adding chitosan, and hatching to obtain the larva fish. According to the breeding method, the sperm and egg quality can be improved, the fertilization rate and the hatching rate are remarkably increased, and according to verification of the embodiment, the fertilization rate ranges from 97.4% to 99.3%, and the hatching rate ranges from 95.6% to 97.1%. The hatched larvae are not deformed, the survival rate is 96%-99%, the quality of the larvae is high, and a good foundation is established for obtaining high-quality hybrid Jinhuasu.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention belongs to the technical field of biological medicines, and discloses application of urolithin A in preparation of medicines or health-care foods for delaying ovarian aging. The invention proves that by supplementing urolithin A, the fertility of the senescent ovary can be improved, the estrus cycle of the senescent ovary can be shortened, the fibrosis level of a senescent ovary matrix can be reduced, the ovary reserve capacity can be improved, the quality of a senescent ovary oocyte can be improved, and the fertilization and embryonic development potential can be improved; it is proved that urolithin A can be used as an effective component for preparing the medicine or health food for delaying ovarian aging.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The present disclosure provides a Chinese Hamster Ovary (CHO) cell comprising one or more exogenous nucleotide sequences, wherein the one or more exogenous nucleotide sequences is inserted into a chromosomal locus of the CHO cell, wherein the chromosomal locus is located within contig NW_023276805.1 of chromosome X. Also provided herein are methods of producing a CHO cell capable of expressing a sequence of interest, methods of expressing a sequence of interest comprising culturing the CHO cell as described herein, and kits comprising the CHO cell as described herein.

The invention provides an establishment method of umbilical cord mesenchymal stem cells with high expression of IGF-1 (Insulin-like Growth Factor 1) and application of the umbilical cord mesenchymal stem cells in premature ovarian failure. The construction method of the umbilical cord mesenchymal stem cells with high expression of IGF-1 comprises the step of transfecting the umbilical cord mesenchymal stem cells with the IGF-1 gene, so that the umbilical cord mesenchymal stem cells highly express IGF-1. The invention also provides application of the umbilical cord mesenchymal stem cell with high expression of IGF-1 in preparation of drugs for treating premature ovarian failure. According to the invention, the IGF-1 gene is transfected to the hUC-MSC, so that the hUC-MSC highly expresses the IGF-1, and the hUC-MSC secretes a large amount of IGF-1. The ovarian function is improved through the immunoregulation effect of hUC-MS, and meanwhile, the effect of resisting apoptosis of granular cells is achieved through IGF-1 secreted by hUC-MS. And the treatment effect on the premature ovarian failure is achieved through synergism of the two effects.

The invention provides a biological material for repairing an ovarian function as well as a preparation method and application thereof, and relates to the technical field of biological materials, a large number of experiments prove that specific biological protein components for reversing the ovarian function in extracellular vesicles are growth differentiation factor 9 (GDF-9) for repairing an ovary, and the biological material has the advantages that the ovarian repairing function mechanism of the specific biological protein components for reversing the ovarian function in the extracellular vesicles is found; according to the present invention, the GDF-9 extracellular vesicles (GDF-9Over-existed Extracellular vesicles, GOEs) are adopted as the active substance, such that the component is effectively extracted and purified so as to achieve the target of targeted therapy.

The embodiment of the invention discloses an ovarian health assessment method and related equipment, the method is applied to first electronic equipment, the first electronic equipment can display a first interface, and the first interface comprises a first control; receiving a first operation acting on the first control; acquiring first data, wherein the first data comprises heart rate variability data of the user in a preset time period; according to the physical sign data of the user, determining an ovary health assessment result; the user sign data comprises first data; the ovarian health assessment result is used for indicating the ovarian health condition of the user in a preset time period; after the preset time period, a second interface is displayed, and the display content of the second interface comprises the ovarian health assessment result. By adopting the method, the ovarian function abnormity of the user can be found in time.

The invention belongs to the technical field of plant extracts, and particularly relates to application of a carob bean extract in a medicine for improving glycometabolism / female polycystic ovarian syndrome. The invention discloses a pharmaceutical composition for improving glycometabolism female polycystic ovarian syndrome. The pharmaceutical composition is prepared from a carob bean extract, baicalein, cedrol, bioactive peptide, biological polysaccharide and auxiliary materials. The composition disclosed by the invention has the effects of reducing blood sugar, reducing blood fat and improving an insulin function, and also has the effects of resisting oxidation, enhancing immunity and the like, and the substances are combined for use, so that a synergistic interaction effect is achieved, and the effect of improving / treating the abnormal glucose metabolism related female polycystic ovarian syndrome is further improved.

The invention discloses application of a substance for detecting the expression level of APOE or MT2 in evaluating the ovarian aging degree. According to the invention, cell and molecular changes related to ovarian aging are explored in spatial resolution by adopting a spatial transcriptome technology, a first non-human primate space-time transcriptome map is established, and potential diagnostic biomarkers and therapeutic targets of age-related human ovarian diseases are disclosed; the method not only promotes the understanding of primate ovarian aging mechanism determinants, but also provides abundant resources for identifying cells and molecular programs which can be used for evaluating ovarian aging and formulating intervention measures for human ovarian aging and related diseases.

The invention provides a preparation method of ovarian stem cells and application of the ovarian stem cells in ovarian aging resistance. More specifically, ovarian stem cells and polypeptide LRP-C5 which is separated from pilose antler polypeptide and has a good ovarian aging treatment effect are prepared and screened from ovaries, ovarian aging of rats can be well treated after the ovarian stem cells and the polypeptide LRP-C5 are used independently or jointly, and the application prospect is good.

The invention discloses application of MY-1B in preparation of medicines for improving ovarian aging, belongs to the technical field of biological medicines, and aims to solve the problems of how to effectively delay ovarian aging and improve ovarian functions. Experiments prove that the mRNA m5C modification level of ovarian granular cells in the ovarian aging process is increased, and the expression level of methylated transferase Nsun2 is increased. Ovarian aging caused by mRNA m5C modification level increase can be improved by supplementing the MY-1B, which is embodied in that the MY-1B can reduce the mRNA m5C modification level of aging nest granular cells; the MY-1B can be used for effectively correcting the orbital cycle disorder of the aged ovary and delaying the decline of the ovarian function; the MY-1B plays an important role in reducing the apoptosis level of granulosa cells in senescent ovaries; the MY-1B can improve the storage capacity of ovaries and enhance the quality of oocytes, so that the fertilization rate and the embryonic development potential of the oocytes are improved.

The invention discloses an artificial intelligence-driven polycystic ovarian syndrome drug target screening method, which comprises the following steps: S1, collecting genome data and hormone level data from the body of a patient, and constructing a patient individualized data set; s2, carrying out denoising processing, missing value filling and standardization on the acquired individual data set of the patient; s3, inputting the standardized individual data set of the patient into a multi-layer neural network model; s4, training the dynamic gene-hormone interaction network model by adopting the training set data; s5, screening out dual regulation and control drug targets highly related to the PCOS pathological mechanism; s6, performing optimization through historical treatment data of the patient and target treatment effect feedback; and S7, outputting the dual regulation and control drug target list in a report form. According to the invention, the efficiency and accuracy of drug target screening are significantly improved.

The invention provides application of sturgeon swimming bladder collagen peptide in preparation of a medicine for premature ovarian failure, and relates to the technical field of protein peptide. According to the method, the sturgeon swim bladder is subjected to resource utilization, so that the waste of the sturgeon swim bladder can be effectively reduced, the sturgeon resource can be sustainably utilized, the extraction rate of the sturgeon swim bladder collagen is relatively high, and industrial production is facilitated; meanwhile, collagen peptide obtained after enzymolysis treatment is conducted through alkaline protease can achieve the effects of preventing, treating, inhibiting and improving the premature ovarian failure.

The invention relates to the technical field of molecular biology, and particularly discloses application of miR-615 in ovarian granular cells. The miR-615 is applied to any one of the following items: preparing a product for promoting the activity and / or proliferation of ovarian granular cells; preparing a product for promoting generation of estradiol and / or progesterone; preparing a product for promoting the expression of the 3 beta-HSD and / or StAR gene; preparing a product for inhibiting ACSL4 gene expression; and preparing a product competitively combined with the lnc-GAM. According to the invention, porcine ovarian granular cells are used as a material, the expression level of lnc-GAM-miR-615 / ACSL4 regulatory axis is up-regulated or down-regulated in the porcine ovarian granular cells by using gene overexpression and interference technologies, and the expression of the lnc-GAM-miR-615 / ACSL4 regulatory axis is determined by detecting cell proliferation activity, hormone secretion level and apoptosis gene expression in combination with a dual-luciferase reporter gene test. And the regulation effect of lnc-GAM mediation on the apoptosis of the porcine ovarian granular cells is researched.

The invention belongs to the technical field of modern agriculture, and particularly relates to a method for creating pseudo male trachinotus ovatus. According to the method for creating the pseudo male trachinotus ovatus, alpha-naphthoflavone and 17 alpha-methyltestosterone are used in a combined mode, feeding induction is started from the 2-month-old period, and finally sperms can be observed in sexual glands of the genetic female trachinotus ovatus in the 8-month-old period. According to the method, the sexual gland of the genetic female trachinotus ovatus (the sexual gland normally develops into an ovary) can be reversed into the testis, in the 8-month-old period, the observed reversal efficiency is 63.6%, compared with single use of alpha-naphthoflavone, the sexual reversal proportion is increased by more than one time, the number and maturity of sperms of the pseudo male trachinotus ovatus are remarkably increased, and the sexual efficiency of the trachinotus ovatus is improved. And the success rate of subsequent all-female golden pomfret creation is greatly improved.

The invention relates to the technical field of biomedical treatment, in particular to bifidobacterium longum subsp. Longum and application thereof in drugs related to reproductive system diseases. The invention provides a strain of Bifidobacterium longum subsp. Longum NCU-06, which is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is January 18, 2023, and the preservation number is CGMCC No.26491. The invention also provides a method for preparing the Bifidobacterium longum subsp. Longum NCU-06. The bifidobacterium longum subsp. Longum NCU-06 has a treatment effect on various female reproductive system diseases, for example, the bifidobacterium longum subsp. Longum NCU-06 can be used for treating endometriosis, ovarian cancer, ovarian cancer parneoplastic thrombocythemia and ovarian hyperstimulation syndrome.

Methods of enhancing or improving fertility are disclosed. Methods of extending reproductive longevity are disclosed. Methods of increasing oocyte mitochondrial mass or preventing a decrease of oocyte mitochondrial mass are disclosed. Methods of improving embryo development or improving embryo fertilization rate are disclosed. Methods of treating or preventing an ovarian disease or condition are disclosed. Methods of reducing, preventing, or delaying perimenopause, menopause, or a symptom thereof are disclosed. The methods include administering an Emblica extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of an Emblica extract, or Fucus extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a Fucus extract, or a chebula extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a chebula extract.

The invention discloses a uterus in-situ endometrium and ectopic endometrium organ induced canceration model as well as an establishment method and application thereof. The method comprises the following steps: extracting endometriosis endometrial cells and endometriosis in-situ endometrial cells, and constructing paired endometriosis endometrial organs and endometriosis in-situ endometrial organs; the endometriosis ectopic endometrial organs and the endometriosis in-situ endometrial organs are subjected to passage; the high-concentration estrogen is used for stimulating endometriosis ectopic endometrial organs and endometriosis in-situ endometrial organs; according to the method, endometriosis organs have certain cell nucleus heterogeneity, a monolayer epithelium structure is developed into a proliferative multi-layer epithelium structure, and a cell model which is convenient to construct and observe and can be cultured for a long time is provided for the pathological process of endometriosis into endometrial adenocarcinoma. The method has important scientific significance on the mechanism research of the subsequent endometriosis malignant transformation into the endometrial adenocarcinoma and the research on key molecules at the early stage of the ovarian endometrial adenocarcinoma.

The invention discloses an MMP2 gene promoter region SNP (Single Nucleotide Polymorphism) site and application thereof in pig breeding. According to the invention, an MMP2 gene promoter region is taken as a research object, and the relevance between the MMP2 gene promoter region and sow sexual maturity is researched by adopting a molecular and cell biology method, so that the situation that g.30088284G > A site and g.30088004C > T site are obviously related to the group maturity day age of Dumet black pigs is found; then different vectors are transfected, and different influences of different genotypes of the sites on the activity of the IRS1 gene promoter are studied. Further, sow ovarian granular cells are used as experimental materials, experimental technologies such as transcriptome sequencing, a total iron colorimetric method and a malondialdehyde colorimetric method are adopted, the influence of the MMP2 gene on the transcriptome level and ferroptosis of the sow ovarian granular cells is researched, and it is found that cell transcriptome differential genes influenced by the MMP2 gene are mainly enriched to signal channels such as cell differentiation; and ferroptosis of cells is promoted.

The invention belongs to the technical field of medicines, and particularly relates to a composition containing mesenchymal stem cells and application of the composition in preparation of products for resisting premature ovarian failure. The invention relates to a composition containing mesenchymal stem cells. The umbilical cord mesenchymal stem cell gel is prepared from the following components in percentage by weight: 10 percent of umbilical cord mesenchymal stem cells, 4 to 6 percent of human serum albumin stock solution, 1 to 2 percent of ginkgo biloba extract, 1 to 3 percent of coix seed oil, 2 to 2.5 percent of flavonol glycoside, 1.1 to 1.3 percent of vitamin E, 0.4 to 0.8 percent of glutathione, 0.5 to 1.5 percent of sodium hyaluronate, 0.5 to 1.0 percent of phycocyanin, 1.2 to 1.8 percent of zinc gluconate, 0.5 to 0.8 percent of heparin calcium, 0.1 to 0.3 percent of pH regulator and the balance of normal saline. The composition disclosed by the invention can be used for preparing products for resisting premature ovarian failure and has a very good effect.

The invention provides a 1, 4-polyisoprene dispersion system, a pharmaceutical active component and application of the 1, 4-polyisoprene dispersion system and the pharmaceutical active component. The dispersion system keeps stable in a gastric acid environment of mammals, does not separate out 1, 4-polyisoprene clots, has no oral toxicity to mammals, and does not contain sensitizers; and the 1, 4-polyisoprene dispersion system comprises a 1, 4-polyisoprene solution dispersion system and a 1, 4-polyisoprene emulsion dispersion system. The 1, 4-polyisoprene dispersion system provided by the invention can be used as an active pharmaceutical ingredient for preparing drugs for treating chronic metabolic diseases including atherosclerotic cardiovascular and cerebrovascular diseases, type 2 diabetes, hypercholesteremia, hypertriglyceridemia, fatty liver, colitis, obesity and polycystic ovarian syndrome.

The invention discloses an ovary-targeting mRNA liposome nanoparticle, a preparation method, a drug compound, a targeting delivery system and application, and relates to the technical field of liposome granules, the ovary-targeting mRNA liposome nanoparticle comprises the following components by mass: 20%-80% of SM-102, 1%-20% of PEG2000, 5%-40% of CHO-HP, 1%-20% of DSCP, and 0.01%-10% of targeting polypeptide, the target polypeptide comprises at least one of the following sequences: LVYKDPARPNTQK, RCGPCRLSSSDCGGPRTQPMACDLP, and CALCRRSTSDCGGPKDHPLT (recombinant human serum albumin), and the target polypeptide comprises at least one of the following sequences. The present invention provides a liposome nanoparticle for targeted ovary and uterus delivery of mRNA. The lipidosome nano-particles are specially researched, developed and designed for mRNA, have a good targeted delivery effect in mRNA in-vivo delivery, and can be applied to the field of targeted drug delivery of ovaries and uteruses. When in use, the kit can be directly prepared with a specific mRNA sequence for use, so that different application requirements can be flexibly met.

The invention discloses a probe and a primer for detecting the expression quantity of sex determining gene amhr2 of silurus meridionalis, the probe comprises an amhr2T probe and an amhr2G probe, and the primer comprises an upstream primer F1 and a downstream primer R1, the invention also discloses a kit comprising the probe and the primer, a method for detecting the expression quantity of the sex determining gene amhr2 of the catfish by using the probe and the primer, application of the probe and the primer in preparation of the kit for detecting the expression quantity of the sex determining gene amhr2 of the catfish, and the probe and the primer. The kit or the method is applied to the detection of the expression quantity of the sex determining gene amhr2 of the silurus meridionalis. The probe and the primer provided by the invention can accurately detect the expression quantity of the ovary or testis amhr2 gene in silurus asotus, and are low in cost, high in efficiency and high in accuracy.

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.